清晨好,您是今天最早来到科研通的研友!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您科研之路漫漫前行!

SMART STOP: A PHASE II CLINICAL TRIAL OF LENALIDOMIDE, TAFASITAMAB, RITUXIMAB, AND ACALABRUTINIB ALONE AND WITH RESPONSE ADAPTED CHEMOTHERAPY IN PATIENTS WITH NEWLY DIAGNOSED DLBCL

作者
Jason R. Westin,Paolo Strati,Dai Chihara,B. Pulsifer,J. Tom,Richard Eric Davis,H. J. Lee,Ranjit K. Nair,Maria Alma Rodriguez,F. Hagemeister,Christopher R. Flowers,Loretta J. Nastoupil,Lei Feng,M. Green,Luis Fayad,Swaminathan P. Iyer,Sairah Ahmed,Raphael Eric Steiner
出处
期刊:Hematological Oncology [Wiley]
卷期号:41 (S2): 837-838
标识
DOI:10.1002/hon.3166_ot17
摘要

Background: Diffuse Large B-cell Lymphoma (DLBCL) is cured in ∼60% of patients by a chemotherapy-based approach which is largely unchanged for decades. We have previously shown the feasibility and significant efficacy of a targeted therapy combination as initial treatment for patients with newly diagnosed LBCL (Smart Start, Westin et al, JCO 2023). BTK inhibitors like acalabrutinib (A) and the immunomodulatory agent lenalidomide (L) have activity as single agents, and result in synthetic lethality when combined in non-GCB DLBCL models. Both the CD19 antibody tafasitamab (T) and CD20 antibody rituximab (R) demonstrated significant clinical activity with L in patients with relapsed DLBCL. L, T, R, and A are also immunomodulatory, shifting from a tumor-mediated immune anergy to an anti-tumor immune response. Study Design and Methods: Smart Stop is a phase II, open-label, single-center clinical trial combining LTRA alone and with cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP) for patients with previously untreated DLBCL (NCT04978584). Eligibility criteria include adult patients with previously untreated DLBCL with adequate organ and bone marrow function. Patients receive lenalidomide (L) 25 mg daily days 1-10, tafasitamab (T) 12 mg/kg IV weekly, rituximab (R) 375 mg/m2 IV day 1, and acalabrutinib (A) 100 mg PO twice daily during a 21 day cycle. All patients receive LTRA for four cycles, unless clinical suspicion of disease progression. PET/CT scan using the 5 point Deauville score (5PS) will determine response, with complete response (CR) defined as a 5PS of 1, 2, or 3. The trial will have two sequential cohorts of 30 patients each. Patients who achieve CR will receive 6 additional cycles of uLTRA, which will include CHOP for 2 cycles (Cohort 1, Group A) or no CHOP (cohort 2, Group C). Patients who achieve less than a CR (Group B or D) will receive LTRA-CHOP for 6 cycles, for a planned 10 cycles of therapy for all patients. We will utilize two decision rules based upon results from cohort 1 to open and complete cohort 2: 1) the probability in Group A of sustained CRR at the end of therapy, 2) the probability in Group A of sustained response at 7 months after end of therapy in the first 10 patients. The primary objectives are to determine the 1A: overall response rate after 4 cycles of LTRA and 1B: CR rate of LTRA +/-CHOP at the end of therapy. The maximum sample size is 60 patients. Secondary objectives include survival outcomes, safety, and outcomes of LTRA without CHOP, LTRA with 2 or 6 cycles of CHOP. Exploratory objectives include determining ctDNA response, immune modulation driven by LTRA, and LTRA response associated characteristics. The trial opened in 5/2022 and is actively recruiting patients. The research was funded by: Incyte/Morphosys, AstraZeneca, and BMS Keywords: ongoing trials Conflicts of interests pertinent to the abstract. J. Westin Consultant or advisory role Kite/Gilead, BMS, Novartis, Genentech, AstraZeneca, Morphosys/Incyte, ADC Therapeutics, Abbvie, SeaGen, MonteRosa, Regeneron Research funding: Kite/Gilead, BMS, Novartis, Genentech, AstraZeneca, Morphosys/Incyte, ADC Therapeutics, Kymera, Calithera

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
nano完成签到 ,获得积分10
3秒前
RZH发布了新的文献求助10
12秒前
机智的如曼完成签到,获得积分10
22秒前
Xzx1995完成签到 ,获得积分10
24秒前
FashionBoy的应助被科研通管家采纳,获得10
27秒前
fairytaler的应助被科研通管家采纳,获得10
27秒前
现代的初之完成签到,获得积分10
33秒前
大模型的应助被蜗牛好好飞采纳,获得10
34秒前
ChatGPT完成签到,获得积分10
36秒前
慕青的应助被蜗牛好好飞采纳,获得10
40秒前
夏同学完成签到 ,获得积分10
41秒前
今后的应助被蜗牛好好飞采纳,获得10
46秒前
wwrjj完成签到,获得积分0
47秒前
搜集达人的应助被cc采纳,获得10
48秒前
大模型的应助被蜗牛好好飞采纳,获得10
51秒前
57秒前
57秒前
御坂10576号完成签到,获得积分10
57秒前
59秒前
义气的雅琴完成签到,获得积分10
1分钟前
cc发布了新的文献求助10
1分钟前
NexusExplorer的应助被蜗牛好好飞采纳,获得10
1分钟前
Harlotte完成签到 ,获得积分0
1分钟前
蒋不惜完成签到,获得积分10
1分钟前
changfox完成签到,获得积分10
1分钟前
hyk完成签到 ,获得积分10
1分钟前
milalala完成签到 ,获得积分10
1分钟前
浚稚完成签到 ,获得积分10
1分钟前
1分钟前
冷傲的夜白完成签到,获得积分10
1分钟前
岳晓燕完成签到 ,获得积分10
1分钟前
1分钟前
清脆代真发布了新的文献求助50
1分钟前
1分钟前
谭访冬完成签到,获得积分10
1分钟前
MUAN完成签到 ,获得积分10
1分钟前
2分钟前
细腻海瑶完成签到,获得积分10
2分钟前
铁瓜李完成签到 ,获得积分10
2分钟前
2分钟前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
plantTFDB 508
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8173230
求助须知:如何正确求助?哪些是违规求助? 9565593
关于积分的说明 21780525
捐赠科研通 7767429
什么是DOI,文献DOI怎么找? 3431542
关于科研通互助平台的介绍 2555764
邀请新用户注册赠送积分活动 2476697